AU2017293778B2 - TGF-beta superfamily heteromultimers and uses thereof - Google Patents

TGF-beta superfamily heteromultimers and uses thereof Download PDF

Info

Publication number
AU2017293778B2
AU2017293778B2 AU2017293778A AU2017293778A AU2017293778B2 AU 2017293778 B2 AU2017293778 B2 AU 2017293778B2 AU 2017293778 A AU2017293778 A AU 2017293778A AU 2017293778 A AU2017293778 A AU 2017293778A AU 2017293778 B2 AU2017293778 B2 AU 2017293778B2
Authority
AU
Australia
Prior art keywords
polypeptide
seq
amino acids
heteromultimer
begins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017293778A
Other languages
English (en)
Other versions
AU2017293778A1 (en
Inventor
Roselyne CASTONGUAY
Asya Grinberg
Ravindra Kumar
Dianne S. Sako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2017293778A1 publication Critical patent/AU2017293778A1/en
Priority to AU2022201603A priority Critical patent/AU2022201603A1/en
Application granted granted Critical
Publication of AU2017293778B2 publication Critical patent/AU2017293778B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017293778A 2016-07-07 2017-07-06 TGF-beta superfamily heteromultimers and uses thereof Ceased AU2017293778B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022201603A AU2022201603A1 (en) 2016-07-07 2022-03-08 TGF-beta superfamily heteromultimers and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662359614P 2016-07-07 2016-07-07
US62/359,614 2016-07-07
US201662404670P 2016-10-05 2016-10-05
US62/404,670 2016-10-05
PCT/US2017/040849 WO2018009624A1 (en) 2016-07-07 2017-07-06 Tgf-beta superfamily heteromultimers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022201603A Division AU2022201603A1 (en) 2016-07-07 2022-03-08 TGF-beta superfamily heteromultimers and uses thereof

Publications (2)

Publication Number Publication Date
AU2017293778A1 AU2017293778A1 (en) 2019-01-24
AU2017293778B2 true AU2017293778B2 (en) 2022-03-24

Family

ID=60913181

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017293778A Ceased AU2017293778B2 (en) 2016-07-07 2017-07-06 TGF-beta superfamily heteromultimers and uses thereof
AU2022201603A Abandoned AU2022201603A1 (en) 2016-07-07 2022-03-08 TGF-beta superfamily heteromultimers and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022201603A Abandoned AU2022201603A1 (en) 2016-07-07 2022-03-08 TGF-beta superfamily heteromultimers and uses thereof

Country Status (6)

Country Link
US (1) US20200071382A1 (enExample)
EP (1) EP3481860A4 (enExample)
JP (2) JP7159148B2 (enExample)
AU (2) AU2017293778B2 (enExample)
CA (1) CA3029890A1 (enExample)
WO (1) WO2018009624A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280435B1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途
AU2019262139A1 (en) * 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
US20220089683A1 (en) * 2018-06-15 2022-03-24 Acceleron Pharma Inc. Bi-and tri-functional fusion proteins and uses thereof
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
EP4433160A1 (en) 2021-11-17 2024-09-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
WO2026125668A1 (en) * 2024-12-13 2026-06-18 Institut National de la Santé et de la Recherche Médicale Peptide derived from endoglin for treating bleeding disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686348B1 (en) 2011-03-17 2015-12-30 Ramot at Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
EP3549952A1 (en) * 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
WO2014055869A1 (en) 2012-10-05 2014-04-10 Acceleron Pharma, Inc. Treatment of cancer with alk1 antagonists
AU2014339898B2 (en) * 2013-10-25 2020-07-23 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
AU2014388308A1 (en) * 2014-03-28 2016-10-27 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (ALK-1) antagonists in the treatment of cancer
WO2015160940A1 (en) 2014-04-15 2015-10-22 President And Fellows Of Harvard College Bi-specific agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CASTONGUAY R. et al., "Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth", J. Biol. Chem. (2011) 286 (34): 30034 - 30046 *

Also Published As

Publication number Publication date
AU2017293778A1 (en) 2019-01-24
JP2019527547A (ja) 2019-10-03
EP3481860A4 (en) 2020-01-22
WO2018009624A1 (en) 2018-01-11
CA3029890A1 (en) 2018-01-11
US20200071382A1 (en) 2020-03-05
AU2022201603A1 (en) 2022-03-31
EP3481860A1 (en) 2019-05-15
JP7159148B2 (ja) 2022-10-24
JP2022172479A (ja) 2022-11-16

Similar Documents

Publication Publication Date Title
US12338273B2 (en) Single-arm type I and type II receptor fusion proteins and uses thereof
US20240158468A1 (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
US20250084388A1 (en) Alk4:actriib heteromultimers and uses thereof
AU2022201603A1 (en) TGF-beta superfamily heteromultimers and uses thereof
US12421295B2 (en) TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
US20230183319A1 (en) Variant actriib proteins and uses thereof
JP2019527547A5 (enExample)
US20210107959A1 (en) Single-arm co-receptor fusion proteins and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired